

CLOSING THE DEAL: MAKING THE RIGHT CONGRESSIONAL DECISION ABOUT PATENT SETTLEMENT AGREEMENTS

Amy C. Waltz*

TABLE OF CONTENTS

I. INTRODUCTION.....	156
II. RELEVANT LAW: INCENTIVES TO SETTLE PATENT INFRINGEMENT SUITS BY AGREEMENT.....	157
A. <i>Patent Law: Conflicting Interests Give Rise to Incentives to Settle</i>	158
B. <i>The Sherman Antitrust Act: Protecting Competition</i>	160
C. <i>The Complete Process: From ANDA to Settlement</i>	161
D. <i>Today's Pharmaceutical Market: Market Incentives to Settle Patent Infringement Suits</i>	162
III. THE HISTORY OF THE DEBATE	164
A. <i>Schering-Plough: Patent Settlement Agreements with Upsher and ESI</i>	165
B. <i>Zeneca: Patent Settlement Agreement with Barr</i>	166
C. <i>Bayer: Patent Settlement Agreement with Barr</i>	167
IV. THE DETAILS OF THE DEBATE	168
A. <i>The Arguments for Settlement: The Courts and the Industry</i>	168
1. <i>The Courts' Reasoning: Consistently Upholding Settlement Agreements</i>	168
2. <i>The Pharmaceutical Industry: Protecting Investments Through Settlement</i>	170
3. <i>The View of the Generic Manufacturers: A Good Business Decision</i>	172
B. <i>The Arguments Against Patent Settlement Agreements: The FTC and the Consumer</i>	173
1. <i>The FTC: Protecting the Consumer</i>	173
2. <i>Consumer Groups and Other Interested Parties</i>	175
V. MAKING THE CALL: THE BEST OPTION FOR CONGRESS.....	176
A. <i>The Call for Congressional Action</i>	176
B. <i>Congress' Options: Codification, Legislation, and Limitation</i>	177

* J.D. Candidate, 2008, Indiana University School of Law—Indianapolis; B.A., 2005, Franklin College of Indiana.